DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
Newron Pharmaceut.
WKN: A0LF18 / Name: Newron Pharmaceut. / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /
11,20 €
-0,71 %
DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
| Unlocking Potential: Discover the transformative power of MetroEHS Pediatric Therapy. Our dedicated team of therapists specializes in ABA, speech, occupational, and feeding therapy, ensuring personalized care for your child's success. Embrace a brighter future with our comprehensive mental health services and convenient teletherapy options.
Neueste Beiträge
BennieRichards in Inter Parfums, Inc. Signs Exclusive Worldwide Fragrance License for Roberto Cavalli, Inter Parfums Inc.